Fosun Pharma subsidiary’s slulimab injection included in Breakthrough Therapy Program
November 21, 2025
Source: drugdu
101
Beijing Business Daily (Reporter Ding Ning) - On the evening of November 20, Fosun Pharma (600196) announced that its subsidiary, Shanghai Henlius Biotech Co., Ltd., and its subsidiary's independently developed slulimab injection (trade name in China: Hanszol) for neoadjuvant/adjuvant chemotherapy in combination with chemotherapy for gastric cancer (GCneo) have been included in the Breakthrough Therapy Program.
The announcement indicates that, as of the date of the announcement, no PD-1-targeting monoclonal antibody drugs have been approved globally for neoadjuvant/adjuvant therapy in gastric cancer. Fosun Pharma stated that inclusion in the Breakthrough Therapy designation process is expected to accelerate the review and market launch of the drug for this indication in China.
https://finance.eastmoney.com/a/202511203570106585.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Multiple batches of quadrivalent influenza virus split vaccine have been sub-packaged and submitted for lot release approval; expected to be released to the market soon after approval December 12, 2025
- Ab&B Bio-Tech CO., LTD. JS Lyophilized Human Rabies Vaccine Initiates Phase III Clinical Trials December 12, 2025
- The ‘Sweetest’ HPV Vaccine Market is Gone | Haibin Interview December 12, 2025
- InnoCare Pharma announced that its first independently developed next-generation TRK inhibitor, zoletrazinib, has been approved for marketing in China December 12, 2025
- Is PD-1/VEGF dual antibody + ADC becoming the standard configuration? December 12, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
